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ELECTROACTIVE POLYMERIC SCAFFOLDS 
AND METHOD FOR DELVERING NERVE 
GROWTH FACTOR TO NERVE TISSUE 
BACKGROUND OF THE INVENTION 
0001. The invention relates to biomaterials, and more par 
ticularly relates to electroactive biomaterials. In its most 
immediate sense, the invention relates to delivery of nerve 
growth factor to nerve tissue, and to implantable electroactive 
scaffolds used for such delivery. 
0002. When a peripheral nerve has a defect of more than 
two centimeters, a biomaterial is needed to repair the defect. 
This is conventionally done using either an autologous nerve 
graft (i.e. by taking a functioning section of a nerve from 
elsewhere in the patient’s body) or using an allograft (i.e. by 
using a section of a nerve that has been removed from another 
living individual or from a cadaver). An autologous graft 
causes a loss of function from the site where the nerve section 
was removed, and an allograft is expensive. It would therefore 
be advantageous to provide a biomaterial having properties 
similar to an autologous nerve graft or a nerve allograft, so 
that the biomaterial could be used to repair peripheral nerve 
defects. 
0003. The invention proceeds from the realization that 
when a polymerizable electrically responsive unit Such as 
pyrrole is anchored by polymerization within a polycaprolac 
tone matrix in order to form an electroactive scaffold upon 
which cells can be cultured, the micro- and nano-topological 
features of the polycaprolactone matrix can be preserved. 
And, when pyrrole is so anchored within a polycaprolactone 
matrix, Schwann cells can be cultured on the scaffold. 
Schwann cells are known to increase the production of nerve 
growth factor when electrically stimulated, and nerve growth 
factor has been demonstrated to promote regeneration of 
nerve tissue. Hence, in accordance with the invention, nerve 
growth factor can be delivered to nerve tissue by implanting 
in the tissue a scaffold in accordance with the invention upon 
which Schwann cells have been cultured, and electrically 
stimulating the Schwann cells. However, use of pyrrole is not 
essential to the practice of the invention. Another polymeriZ 
able unit can be used instead of pyrrole, provided the product 
is electrochemically responsive. 
0004 While the invention is motivated by the need to 
deliver nerve growth factor to repair nerve tissue, it can have 
other applications. Scaffolds inaccordance with the invention 
can be used to deliver drugs, antibacterial agents, and anti 
fungal agents. They can also be used as electroactive actua 
tors capable of mechanotransduction of stem cells. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0005. The invention will be better understood with refer 
ence to the following illustrative and non-limiting drawing, in 
which: 
0006 FIG. 1 shows the experimental setup used to elec 
trically stimulate rat Schwann cells which increases the pro 
duction of nerve growth factor by the Schwann cells. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
1. Production of Electroactive Polycaprolactone-Based 
Scaffolds 
0007 Initially, pyrrole was purified by passage over basic 
alumina. A polycaprolactone matrix with aligned pores was 
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placed in a solution of the pyrrole (291 uL. 84 mM), 1 eq.) 
and polystyrenesulfonate (0.799 g, 84 mM), 1 eq., Mn 70 
kDa) in a solvent of distilled water (50 mL). Samples were 
sonicated for five minutes and cooled to 4°C. for one hour. 
Thereafter, ferric chloride (1.848 g. 228 mM, 2.7 eq.) was 
added as an initiator, the mixture was shaken to assure disso 
lution of the ferric chloride, and the shaken mixture was then 
incubated for a further twenty four hours at 4°C. Electroac 
tive scaffolds with an interpenetrating network of polypyrrole 
and polystyrenesulfonate) were removed from the reaction 
mixture, placed in fresh distilled water, sonicated for five 
minutes, and then exhaustively washed (to remove mono 
mers, oligomers and initiators) with deionized water until the 
water was clear, colorless and the pH was neutral (approxi 
mately forty-eight hours). The scaffolds were then dried 
under high vacuum at 21°C. 
0008 Electroactive polycaprolactone-based scaffolds so 
prepared have their microscale and nanoscale topological 
properties preserved. This is advantageous because clinical 
evidence suggests that micro- and nano-topographical fea 
tures incorporated into scaffolds is beneficial for the restora 
tion of nerve tissue. 
2. Preparation and Sterilization of Electroactive-Coated 
Polycaprolactone-Based Scaffolds 
0009. The dried scaffolds with aligned pores were incu 
bated in an aqueous solution of poly-D-lysine (PDL, 50 
ug/mL) for one hour and then washed thoroughly with sterile 
water to remove any weakly adsorbed poly-D-lysine (ex 
changing the water every ten minutes for one hour). Samples 
were inserted in untreated polystyrene tissue culture plates 
and sterilized by incubation in 70% ethanol solution, fol 
lowed by exposure to UV for sixty minutes. 
3. In Vitro Culture of Human Dermal Fibroblasts 
0010 Growth medium for human dermal fibroblasts was 
composed of high glucose Dulbecco's Modified Eagle 
Medium (DMEM, 440 mL); fetal bovine serum (50 mL): 
antibiotic-antimycotic (5 mL); non-essential amino acids (5 
mL), and 2 ng/mL basic fibroblast growth factor. The steril 
ized scaffolds were incubated for thirty minutes under three 
millimeters of this growth medium. The growth medium was 
aspirated and replaced before seeding with human dermal 
fibroblasts at 5,000 cells/cm under three millimeters of 
medium, and incubated at 37° C., 95% humidity, and a CO 
content of 5%. Cell viability before starting the experiment 
was determined by the Trypan Blue (Sigma, USA) exclusion 
method, and the measured viability exceeded 95% in all 
cases. After two days the medium was aspirated, the scaffolds 
were washed gently with phosphate-buffered saline, the cells 
were fixed with 4% paraformaldehyde in phosphate-buffered 
saline for fifteen minutes, and the scaffolds were washed 
again with phosphate-buffered saline (3x1 mL). 
0011. The human dermal fibroblasts were observed to 
adhere to the scaffolds. 
4. In Vitro Culture of Schwann Cells 
0012 Schwann cell growth medium was composed of: 
25.5 mL of low glucose Dulbecco's Modified Eagle Medium 
(DMEM); 8.5 mL of GIBCOR Ham's F-12 Nutrient Mixture: 
350 uL Penicillin Streptomycin (1% of the final volume); 350 
uL N2 supplement (2% of the final volume); Forskolin 5 
uM; and Neuregulin-1B (50 ng/mL). The sterilized scaffolds 
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were incubated for thirty minutes under three millimeters of 
this growth medium. The growth medium was aspirated and 
replaced before seeding with rat Schwann cells at 5,000 cells/ 
cm under three millimeters of medium, and incubated at 37° 
C., 95% humidity, and a CO, content of 5%. Cell viability 
before starting the experiment was determined by the Trypan 
Blue (Sigma, USA) exclusion method, and the measured 
viability exceeded 95% in all cases. After two days the 
medium was aspirated, the scaffolds were washed gently with 
phosphate-buffered saline, the cells were fixed with 4% 
paraformaldehyde in phosphate-buffered saline for fifteen 
minutes, and the scaffolds were washed again with phos 
phate-buffered saline (3x1 mL). 
0013 The Schwann cells were observed to adhere to the 
scaffolds. 
5. Electrical Stimulation of Schwann Cells 
0014 Non-conductive glass slides, polycarbonate wells 
(2.5 cm square polycarbonate blocks 1 cm thick, sides of 2.5 
cm, with 0.9 cm square holes cut out of them), Dow Corning R 
high vacuum grease, and medium binder clips were sterilized 
by autoclave. Polystyrene petri dishes (diameter of 10 cm) 
had holes drilled in their sides and were sterilized by exposure 
to ultraviolet radiation for sixty minutes. Adhesive-backed 
copper tape (5 mm width, Ted Pella, Inc.), waterproof Kap 
ton(R) tape (1 cm width, Fisher Scientific, Waltham, Mass.), 
wires and alligator clips were sterilized by exposure to ultra 
violet radiation for sixty minutes. 
00.15 Electroactive polycaprolactone-based sterilized 
scaffolds with aligned pores 10 were placed on sterilized 
glass slides 12 and secured in position with two thin Strips 14, 
16 of sterilized adhesive-backed copper tape that were 
attached to the scaffolds 10, parallel to one another, separated 
by a distance of approximately four centimeters. A polycar 
bonate well 18 for holding the Schwann cell growth medium 
was mounted watertight to the slide 12. The counter and 
reference electrodes (20 and 22 respectively) were connected 
together to the strip 16, and the working electrode 24 was 
clipped to the strip 14. Schwann cells were plated and cul 
tured as described above. A potential step of +50 mV/mm was 
placed across the substrate for the duration of 1 hour, after 
which the wires were disconnected and the substrates cul 
tured as normal. 
0016. The amount of nerve growth factor expressed by rat 
Schwann cells under electrical stimulation was measured and 
compared with the amount of nerve growth factor expressed 
by rat Schwann cells that were not electrically stimulated and 
that served as controls. The electrically stimulated cells in the 
electroactive PCL-based tissue scaffolds with aligned pores 
10 were exposed to a potential difference of 50 mV/mm. 
0017. The concentration of NGF in the medium (in 
pg/mL) was determined (using a Rat NGF ELISA Kit, Insight 
Genomics, Falls Church, Va.) immediately after electrical 
stimulation and thereafter in intervals of twelve hours for 
three days. There were no significant differences in NGF 
production by Schwann cells in any of the non-stimulated 
controls over the three day study, whereas, after forty eight 
hours in culture the rat Schwann cells responded to the elec 
trical stimulation by increased production of NGF, a trend 
that was markedly more apparent during the following twenty 
four hours to approximately three times the amount produced 
by an equivalent number of rat Schwann cells cultured with 
out electrical stimulation. Such increases in nerve growth 
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factor production have been shown to encourage neurite out 
growth from neurons in a number of studies. 
6. In-Vitro Degradation of Electroactive 
Polycaprolactone-Based Scaffolds 
0018 To demonstrate that enzymatic/hydrolytic degrada 
tion of the electroactive polycaprolactone-based scaffolds is 
possible, the scaffolds were incubated in phosphate-buffered 
saline in the absence or presence of a high concentration (4 
units/mL) of cholesterolesterase, an enzyme known to hydro 
lyze ester bonds in polyesters. When incubated in phosphate 
buffered saline for twelve days the mass of the scaffolds did 
not change significantly because hydrolysis of phosphate 
buffered saline occurs very slowly. The presence of the 
esterase increased the rate of hydrolysis, resulting in an 
approximately 50% mass loss over 12 days. The presence of 
the electroactive polyelectrolyte complex of polypyrrole and 
polystyrenesulfonate appears to increase the hydrophilicity 
of the scaffolds allowing the enzyme to more easily access the 
polycaprolactone chains. The scaffolds are likely to degrade 
slowly if administered in vivo (over the period of several 
months) in line with other polycaprolone-based materials, 
leaving behind the residual water insoluble polyelectrolyte 
complex of polypyrrole and polystyrenesulfonate that pre 
clinical trials have shown to be relatively non-immunogenic. 
Indeed, histological analyses of tissue in the vicinity of poly 
pyrrole-based tissue scaffolds implanted Subcutaneously or 
intramuscularly in rats, showed immune cell infiltration com 
parable to FDA-approved poly(lactic acid-co-glycolic acid) 
Schmidt C. E., Shastri V.R., Vacanti J. P. Langer R: Stimu 
lation of neurite outgrowth using an electrically conducting 
polymer. Proc Natl Acad Sci USA 1997, 94:8948-8953 or 
poly(D.L-lactide-co-glycolide). Wang Z. Roberge C, Dao L. 
H. Wan Y. Shi G. Rouabhia M. Guidoin R. Zhang Z:. In vivo 
evaluation of a novel electrically conductive polypyrrole/poly 
(D.L-lactide) composite and polypyrrole-coated poly(D.L- 
lactide-co-glycolide) membranes. J Biomed Mater Res A 
2004, 70:28-38 Similarly, there was no significant inflamma 
tion in the vicinity of polypyrrole-based materials implanted 
in the coronary artery of rats after 5 weeks, Mihardja S. S., 
Sievers R. E., Lee R. L.: The effect of polypyrrole on arterio 
genesis in an acute rat infarct model. Biomaterials 2008, 
29:4205-4210 sciatic nerve guidance channels implanted in 
rats after 8 weeks. Durgam H. Sapp S. Deister C, Khaling Z. 
Chang E. Luebben S, Schmidt C. E.: Novel degradable co 
polymers of polypyrrole Support cell proliferation and 
enhance neurite out-growth with electrical stimulation. J Bio 
mater Sci Polym Ed 2010, 21: 1265-1282 or electrodes in rat 
brains after 3 or 6 weeks. George P. M., Lyckman A. W., 
LaVan D. A., Hegde A, Leung Y. Avasare R, Testa C, Alex 
ander P. M., Langer R. Sur M. Fabrication and biocompat 
ibility of polypyrrole implants suitable for neural prosthetics. 
Biomaterials 2005, 26:351 1-3519 
7. Alternates to Pyrrole 
0019. As stated above, use of pyrrole is not essential to 
practicing the invention. Another polymerizable unityielding 
an electrochemically-responsive polymer can be used instead 
of pyrrole. Examples of Such polymerizable units yielding 
electrochemically-responsive polymers are: an aniline, an 
aniline derivative, a furan, a furan derivative, a thiophene, a 
thiophene derivative, a ferrocene, a ferrocene derivative, a 
porphyrin; and a porphyrin derivative. 
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0020. Use of ferric chloride as an initiator is not necessary 
to practice the invention. Other initiators, such as ammonium 
persulfate and peroxides can be used instead. So, too, water 
need not be used as the solvent; other solvents can also suit 
able as long as the polycaprolactone is insoluble in them. 
Quite obviously, the initiator and solvent to be used will be 
determined by the choice of polymerizable electrochemical 
unit. 
8. Nerve Tissue Therapy 
0021. As stated above, Schwann cells are known to pro 
duce nerve growth factor when electrically stimulated. In 
accordance with the invention, Schwann cells are cultured on 
the above-described scaffolds and the scaffolds with the 
Schwann cells cultured on them are implanted into the periph 
eral nerve tissue to be repaired. Delivery of nerve growth 
factor to the nerve tissue is accomplished by applying a Volt 
age across the scaffolds and thereby electrically stimulating 
the Schwann cells. The nerve growth factor thereby produced 
promotes regeneration of nerve tissue. 
0022. Although a preferred embodiment has been 
described above, the scope of the invention is limited only by 
the following claims: 
1. An electroactive tissue scaffold, comprising: 
a. a polycaprolactone matrix; and 
b. a polymerizable unit yielding an electrochemically 
responsive polymer located in the pores of the matrix 
and anchored thereto by polymerization. 
2. The scaffold of claim 1, wherein the scaffold is biode 
gradable. 
3. The scaffold of claim 1, wherein the polymerizable unit 
yielding an electrochemically responsive polymer is an aro 
matic compound. 
4. The scaffold of claim3, wherein the aromatic compound 
is heterocyclic. 
5. The scaffold of claim 4, wherein the heterocyclic aro 
matic compound is a pyrrole. 
6. The scaffold of claim 1, wherein the polymerizable unit 
yielding an electrochemically responsive polymer is selected 
from a group consisting of: 
a. an aniline; 
b. an aniline derivative; 
c. a furan; 
d. a furan derivative; 
e. a thiophene; 
f, a thiophene derivative; 
g. ferrocene; 
h. a ferrocene derivative; 
i. a porphyrin; and 
j. a porphyrin derivative. 
7. The scaffold of claim 6, wherein the polymerizable unit 
yielding an electrochemically responsive polymer is selected 
from a group consisting of: 
a. 3.4-ethylenedioxythiophene; and 
b. a derivative of 3,4-ethylenedioxythiophene. 
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8. The scaffold of claim 1, wherein the scaffold is bioerod 
ible. 
9. An electroactive tissue scaffold produced by a process 
compr1S1ng: 
a. obtaining polycaprolactone; 
b. obtaining a polymerizable unit that yields an electro 
chemically responsive polymer; and 
c. polymerizing the electrochemically responsive unit and 
the polycaprolactone in a solvent, the solvent being cho 
sen such that the polycaprolactone is insoluble therein. 
10. A method of manufacturing an electroactive tissue 
scaffold, comprising the following steps: 
a. obtaining polycaprolactone; 
b. obtaining a polymerizable unit that yields an electro 
chemically responsive polymer; and 
c. initiating a polymerization of the polycaprolactone and 
the electrochemically responsive unit in the presence of 
a solvent in which the polycaprolactone is insoluble. 
11. The method of claim 10, wherein the solvent is water 
and the polymerizable unit that yields an electrochemically 
responsive polymer is chosen such that the scaffold is bio 
erodible. 
12. The method of claim 11, wherein the polymerizable 
unit that yields an electrochemically responsive polymer is an 
aromatic compound. 
13. The method of claim 12, wherein the aromatic com 
pound is heterocyclic. 
14. The method of claim 13, wherein the polymerizable 
unit that yields an electrochemically responsive polymer is a 
pyrrole derivative. 
15. The method of claim 10, wherein the polymerizable 
unit that yields an electrochemically responsive polymer is 
pyrrole, the solvent is water, and the initiating step is carried 
out using polystyrenesulfonate and ferric chloride. 
16. The method of claim 15, further comprising the step of 
washing to remove monomers, oligomers, and initiators. 
17. A method of manufacturing a polycaprolactone-based 
electroactive tissue scaffold, comprising the following steps: 
a. obtaining a polycaprolactone matrix: 
b. obtaining pyrrole; 
c. polymerizing the pyrrole in an aqueous solution that 
includes the polycaprolactone matrix, polystyrene 
sulfonate and ferric chloride to produce a polycaprolac 
tone-based electroactive scaffold; and 
d. washing the polycaprolactone-based electroactive scaf 
fold to remove the ferric chloride and unbound polysty 
renesulfonate. 
18. A method of delivering nerve growth factor to nerve 
tissue, comprising the following steps: 
a. culturing Schwann cells on an electroactive tissue scaf 
fold: 
b. implanting the scaffold and cultured Schwann cells into 
the peripheral nerve tissue to be repaired; and 
c. electrically stimulating the Schwann cells by placing a 
voltage across the scaffold. 
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